| Ki, µM |
In vitro prototypical probe substrates | | | |
E2Gb | 0.118 ± 0.015 | 0.585 ± 0.074 | 26.4 ± 2.1 |
E1Sb | 0.732 ± 0.224 | 6.96 ± 1.31 | 381 ± 60 |
BSPb | 0.694 ± 0.149 | 2.75 ± 0.62 | 173 ± 34 |
Clinically used substrate drugs | | | |
Pitavastatin | 0.228 ± 0.027 | 1.07 ± 0.08 | 58.8 ± 10.7 |
Atorvastatin | 0.160 ± 0.016 | 0.922 ± 0.122 | 46.0 ± 8.9 |
Fluvastatin | 0.157 ± 0.016 | 1.05 ± 0.19 | 72.7 ± 8.7 |
Rosuvastatin | 0.301 ± 0.031 | 0.952 ± 0.098 | 63.6 ± 8.4 |
Pravastatin | 0.184 ± 0.046 | 0.653 ± 0.117 | 9.65 ± 2.79 |
Repaglinide | 0.0857 ± 0.0330 | 0.598 ± 0.198 | 48.3 ± 18.6 |
Nateglinide | 0.244 ± 0.038 | 0.358 ± 0.079 | 252 ± 100 |
Glibenclamide | 0.102 ± 0.005 | 0.442 ± 0.102 | 29.6 ± 5.2 |
Bosentan | 0.206 ± 0.056 | 0.694 ± 0.211 | 36.6 ± 5.8 |
Valsartan | 0.138 ± 0.017 | 0.377 ± 0.022 | 13.4 ± 0.3 |
Torasemide | 0.486 ± 0.112 | 1.23 ± 0.30 | 49.5 ± 10.8 |
Fexofenadine | 0.0771 ± 0.0100 | 0.423 ± 0.032 | 31.4 ± 4.3 |